Company News

Share this article:
Merck struck a licensing deal with Portola Pharmaceuticals for betrixaban, an experimental anti-blood clotting drug.  According to an AP report, Merck will pay Portola $50 million initially, and a possible total of $470 million if certain goals are met.

Pfizer will appeal the Canadian Federal Court's decision that deemed a patent for Norvasc invalid. The civil action was brought by Ratiopharm, a generics manufacturer. Ratiopharm was granted permission to sell a generic version of the hypertension drug, based on the decision.
Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.